A new drug has been launched - Troplastim®
Mir-Pharm announces successful registration of a new haemostatic agent.
Moscow, October 2024
The company JSC ‘OHPC’ together with LLC ‘Gelespon’ developed and released a new drug with full-cycle synthesis Troplastim® , INN - Avatrombopag. Sales and promotion are handled by Mir-Pharm Ltd.
Avatrombopag is a haemostatic agent, an oral, low molecular weight thrombopoietin receptor agonist (TPA), which stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in increased platelet production. Avatrombopag does not compete with TPE for binding to the TPE receptor and has an additive effect on platelet production with TPE.
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.